Released May 6, 2025, after the close
10-Q filed May 6, 2025, 36 days after period end · 0000950170-25-064606
Q1 2025 · 10-Q
Revenue$20.22M$20.22M −55.6% vs Q1 2024+2,172.1% vs Q4 2024
Net Income-$26.03M-$26.03M N/M vs Q1 2024N/M vs Q4 2024
EPS Diluted-$0.07-$0.07 N/M vs Q1 2024no prior Q4 2024 on file
Gross Profit$11,049,000−54.3%
Operating Income-$26,970,000N/M
Operating Cash Flow-$30,283,000N/M
Free Cash Flowderived-$35,337,000N/M
Margins · derived
Gross margin54.6%+1.5 pt vs Q1 2024
Operating margin-133.4%−1.2 pt vs Q1 2024
Net margin-128.7%−58.1 pt vs Q1 2024
What the release said
The release
Same quarter
| Metric | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Revenue | $20.22M | $45.54M | $25.12M | $26.50M |
| Net Income | -$26.03M | -$32.16M | -$16.84M | -$76.29M |
| EPS Diluted | -$0.07 | -$0.27 | -$0.21 | -$0.99 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR